Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration
Some studies suggest that recent common coronavirus (CCV) infections are associated with reduced COVID-19 severity upon SARS-CoV-2 infection. We completed serological assays using samples collected from health care workers to identify antibody types associated with SARS-CoV-2 protection and COVID-19 symptom duration. Rare SARS-CoV-2 cross-reactive antibodies elicited by past CCV infections were not associated with protection; however, the duration of symptoms following SARS-CoV-2 infections was significantly reduced in individuals with higher common betacoronavirus (βCoV) antibody titers. Since antibody titers decline over time after CCV infections, individuals in our cohort with higher βCoV antibody titers were more likely recently infected with common βCoVs compared with individuals with lower antibody titers. Therefore, our data suggest that recent βCoV infections potentially limit the duration of symptoms following SARS-CoV-2 infections through mechanisms that do not involve cross-reactive antibodies. Our data are consistent with the emerging hypothesis that cellular immune responses elicited by recent common βCoV infections transiently reduce symptom duration following SARS-CoV-2 infections.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
JCI insight - 6(2021), 16 vom: 23. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gouma, Sigrid [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adaptive immunity |
|---|
| Anmerkungen: |
Date Completed 31.08.2021 Date Revised 19.10.2023 published: Electronic UpdateOf: medRxiv. 2021 Apr 19;:. - PMID 33907765 Citation Status MEDLINE |
|---|
| doi: |
10.1172/jci.insight.150449 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327829842 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327829842 | ||
| 003 | DE-627 | ||
| 005 | 20231225201641.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1172/jci.insight.150449 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1092.xml |
| 035 | |a (DE-627)NLM327829842 | ||
| 035 | |a (NLM)34237028 | ||
| 035 | |a (PII)150449 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gouma, Sigrid |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.08.2021 | ||
| 500 | |a Date Revised 19.10.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateOf: medRxiv. 2021 Apr 19;:. - PMID 33907765 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Some studies suggest that recent common coronavirus (CCV) infections are associated with reduced COVID-19 severity upon SARS-CoV-2 infection. We completed serological assays using samples collected from health care workers to identify antibody types associated with SARS-CoV-2 protection and COVID-19 symptom duration. Rare SARS-CoV-2 cross-reactive antibodies elicited by past CCV infections were not associated with protection; however, the duration of symptoms following SARS-CoV-2 infections was significantly reduced in individuals with higher common betacoronavirus (βCoV) antibody titers. Since antibody titers decline over time after CCV infections, individuals in our cohort with higher βCoV antibody titers were more likely recently infected with common βCoVs compared with individuals with lower antibody titers. Therefore, our data suggest that recent βCoV infections potentially limit the duration of symptoms following SARS-CoV-2 infections through mechanisms that do not involve cross-reactive antibodies. Our data are consistent with the emerging hypothesis that cellular immune responses elicited by recent common βCoV infections transiently reduce symptom duration following SARS-CoV-2 infections | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Adaptive immunity | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Immunology | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Weirick, Madison E |e verfasserin |4 aut | |
| 700 | 1 | |a Bolton, Marcus J |e verfasserin |4 aut | |
| 700 | 1 | |a Arevalo, Claudia P |e verfasserin |4 aut | |
| 700 | 1 | |a Goodwin, Eileen C |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Elizabeth M |e verfasserin |4 aut | |
| 700 | 1 | |a McAllister, Christopher M |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Shannon R |e verfasserin |4 aut | |
| 700 | 1 | |a Dunbar, Debora |e verfasserin |4 aut | |
| 700 | 1 | |a Fiore, Danielle |e verfasserin |4 aut | |
| 700 | 1 | |a Brock, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Weaver, JoEllen |e verfasserin |4 aut | |
| 700 | 1 | |a Millar, John |e verfasserin |4 aut | |
| 700 | 1 | |a DerOhannessian, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Unit, The UPenn Covid Processing |e verfasserin |4 aut | |
| 700 | 1 | |a Frank, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Rader, Daniel J |e verfasserin |4 aut | |
| 700 | 1 | |a Wherry, E John |e verfasserin |4 aut | |
| 700 | 1 | |a Hensley, Scott E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JCI insight |d 2016 |g 6(2021), 16 vom: 23. Aug. |w (DE-627)NLM257703918 |x 2379-3708 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2021 |g number:16 |g day:23 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1172/jci.insight.150449 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2021 |e 16 |b 23 |c 08 | ||